Cargando…
Selective antagonism of cJun for cancer therapy
The activator protein-1 (AP-1) family of transcription factors modulate a diverse range of cellular signalling pathways into outputs which can be oncogenic or anti-oncogenic. The transcription of relevant genes is controlled by the cellular context, and in particular by the dimeric composition of AP...
Autores principales: | Brennan, Andrew, Leech, James T., Kad, Neil M., Mason, Jody M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488417/ https://www.ncbi.nlm.nih.gov/pubmed/32917236 http://dx.doi.org/10.1186/s13046-020-01686-9 |
Ejemplares similares
-
The effect of helix-inducing constraints and downsizing upon a transcription block survival-derived functional cJun antagonist
por: Brennan, Andrew, et al.
Publicado: (2022) -
In vitro single molecule and bulk phase studies reveal the AP-1 transcription factor cFos binds to DNA without its partner cJun
por: Leech, James T., et al.
Publicado: (2022) -
Selection and Characterization of a DNA Aptamer That Can Discriminate between cJun/cJun and cJun/cFos
por: Walters, Ryan D., et al.
Publicado: (2014) -
p27 transcriptionally coregulates cJun to drive programs of tumor progression
por: Yoon, Hyunho, et al.
Publicado: (2019) -
Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
por: Xu, Manman, et al.
Publicado: (2022)